SCHEMBL2208053

SCHEMBL2208053

CC(C)(C)C1CCC2(CC1)CC(C(=O)Nc1cc(NS(C)(=O)=O)ccc1F)=NO2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 3/20 0.46
EPHX2 P34913 3/20 0.36
CSF1R P07333 1/20 0.34
TRPV1 Q8NER1 3/20 0.33
PLA2G7 Q13093 1/20 0.33
MAPK14 Q16539 2/20 0.33
S1PR1 P21453 1/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ADRA2C P18825 1/20 0.32
ADRA1A P35348 1/20 0.32
ADRA1B P35368 1/20 0.32
ITGB3 P05106 1/20 0.32
ITGB1 P05556 1/20 0.32
ITGAV P06756 1/20 0.32
ITGA2B P08514 1/20 0.32
ITGA5 P08648 1/20 0.32
CNR1 P21554 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2204894 0.93 GPR119 (0.42) GPR119TRPV1SMN1; SMN2MAPT
SCHEMBL2209037 0.91 GPR119 (0.43) GPR119EPHX2TRPV1MAPK14LMNA
SCHEMBL2206230 0.88 GPR119 (0.44) GPR119TRPV1
SCHEMBL2208732 0.86 GPR119 (0.46) GPR119MAPK14LMNATSHRMAPK1
SCHEMBL4619905 0.85 GPR119 (0.34) GPR119EPHX2TRPV1MAPK14ADRA2C
SCHEMBL4346000 0.80 GPR119 (0.41) GPR119TRPV1LMNATSHRMAPK1
SCHEMBL2205140 0.80 EPHX2 (0.48) EPHX2TRPV1MAPK14NR1H4
SCHEMBL2208558 0.80 EPHX2 (0.48) EPHX2TRPV1MAPK14NR1H4
SCHEMBL2204827 0.80 EPHX2 (0.48) EPHX2TRPV1MAPK14NR1H4
SCHEMBL2210458 0.80 GPR119 (0.40) GPR119TRPV1LMNASMN1; SMN2ITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7981883-B2 Substituted spiro-compounds and the use thereof for producing medicaments GRUENENTHAL GMBH (DE) 2011-07-19 US claimed
US-20090275628-A1 Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments GRUENENTHAL GMBH (DE) 2009-11-05 US claimed
EP-1888542-A1 SUBSTITUTED SPIRO-COMPOUNDS AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2008-02-20 EP claimed
WO-2006136245-A1 SUBSTITUTED SPIRO-COMPOUNDS AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2006-12-28 WO claimed
US-7981883-B2 Substituted spiro-compounds and the use thereof for producing medicaments GRUENENTHAL GMBH (DE) 2011-07-19 US disclosed
US-20090275628-A1 Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments GRUENENTHAL GMBH (DE) 2009-11-05 US disclosed
EP-1888542-A1 SUBSTITUTED SPIRO-COMPOUNDS AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2008-02-20 EP disclosed
WO-2006136245-A1 SUBSTITUTED SPIRO-COMPOUNDS AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275628-A1 Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments REN, PKD1, PKD2 GPR119 3262/4885EPHX2 1541/4885CSF1R 4611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.